Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Barnett, A. H
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Summarising the use of thiazolidinediones with insulin

Anthony H Barnett

Undergraduate Centre, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS. UK, anthony.barnett{at}heartofengland.nhs.uk

Both insulin resistance and pancreatic beta-cell function normally contribute to the development of type 2 diabetes, with the latter also responsible for the progression of the disease. Successful management inevitably requires therapy that addresses both underlying defects. Clinical trials support the use of agents with complementary mechanisms of action. The major therapeutic effect of the thiazolidinediones in type 2 diabetes is improvement of insulin sensitivity and they are thus ideally suited for combination therapy with insulin, although they can also be used as monotherapy or in dual or triple oral agent therapy. In addition to improving glycaemic control, the thiazolidinediones have favourable effects on a number of cardiovascular risk factors and may reduce the risk of long-term diabetes-related complications independent of their effects on glycaemic control. Combination therapy of a thiazolidinedione with insulin is no longer contraindicated in Europe, and this combination can provide improvements in glycaemic control that are additive to the effects of insulin alone.

Key Words: combination therapy • insulin • pioglitazone • rosiglitazone • thiazolidinedione • type 2 diabetes mellitus.

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 2, 75-80 (2007)
DOI: 10.1177/14746514070070020501
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?